ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors
He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.
Vitamin D Slows Biological Aging? New 4-Year Study on Telomeres! Ep. 1244 JUN 2025
Vitamin D Slows Biological Aging? New 4-Year Study on Telomeres! Ep. 1244 JUN 2025
A recent sub-study of the large-scale VITamin D and OmegA-3 TriaL (VITAL), published in The American Journal of Clinical Nutrition, has revealed significant findings regarding vitamin D and cellular aging. Researcher…
Legend Biotech's Race to Make Cell Therapy Mainstream
“Once a scientist, forever a scientist,” says Legend Biotech CEO Ying Huang as he joins Bloomberg Intelligence analyst Sam Fazeli to share his unconventional journey from the lab bench to Wall Street and back to biotech leadership. Dr. Huang explains how a dream led him from equity research to deve…
Youth Voices Across Borders: Reflections on U.S.-China Dialogue
Amid the complexities of China-U.S. relations, youth exchanges remain an indispensable bridge. In this episode, Professor Da Wei, Director of the Center for International Security and Strategy at Tsinghua University, moderates a conversation with Ying Huang, PhD candidate in International Relations…
#365 Ending HIV, Accelerating COVID: Dr. Larry Corey’s Legacy in Vaccine Science
The 11th annual Raw Science Film Festival took place this past weekend in New York City. We were lucky enough to be invited and had the honor of interviewing Dr. Larry Corey in-person. He is a renowned expert in virology, immunology and vaccine development who was featured throughout the film “Endi…
Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia
He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.
Legend Biotech CEO (LEGN) on JNJ Partnership & Rapidly Scaling Cancer Drug Revenue
Dr. Ying Huang, CEO of Legend Biotech (LEGN), explains the work his company does on white blood cell cancer. They grew revenue from the drug 84% last quarter to over $500 million, and expect to turn a profit in 2026. He discusses their partnership with Johnson & Johnson (JNJ), international expansi…
ASH 2025: Legend Biotech CEO Ying Huang discusses new long-term Carvykti data, looming competition, a CD19+CD20 γδ program, and in vivo CAR-T
He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs.
Ep.212: Research & Real Talk Episode 20 with GUEST John Bauer (he’s baaaack!!)
The research and real talk keep rolling in! Join Jenny and John yet again as they dive into some new revelations on vitamin D, Alzheimer’s disease, and ultra-processed foods. Then, John brings the heat with an enthralling round of “Real Talk? Or Bro-Science?”
Guest Name/ Guest Company / Guest or Co…
Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals
Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs make it to market, and the Trump administration opens a new round of Medicaid drug pricing deals.
MESIN PENCARI PODCAST
Anda dapat menggunakan situs web kami untuk mencari podcast3,825,960dan episode195,970,560menurut orang, tempat, atau topik.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
Sunting
Terima kasih telah membantu agar basis data podcast tetap terbaru
